Ysios Capital, a CataloniaBio & HealthTech member, has closed its third fund Ysios BioFund III at 216 million euros.
The venture capital firm specialised in the biotechnology sector will invest in 15 start-ups and development-stage companies in Europe and the US. The total investment size per company will typically be of up to €20 million.
More than 60% of the portfolio has already been constructed, with eight investments made in the last 12 months: Ona Therapeutics (oncology), SpliceBio (gene therapy), VarmX (blood clotting), Lava Therapeutics (oncology), SparingVision (gene therapy), Synendos (neuropsychiatry), Adcendo (oncology) and Cytoki (inflammation).
After 13 years of experience, Ysios has invested in 34 companies, including several of Spain’s biotech success stories, and has brought 14 innovative medical products to market.
In 2019, Ysios won CataloniaBio & HealthTech Biosuccess Award.
Photo: The management team, Raúl Martín-Ruiz, Cristina Garmendia, Julia Salaverria, Karen Wagner, Joël Jean-Mairet and Paula Olazábal - © Ysios Capital
You may also be interested in:
Comentaris